OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

Associated equity: OpGen

OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.

OpGen — 5 videos in collection

This interactive webinar with OpGen’s CEO Oliver Schacht, CFO Tim Dec and COO Johannes Bacher highlights recent progress in the fight against Antimicrobial Resistance. The presentation includes updates on R&D progress, FDA and NMPA regulatory reviews and pending approvals, upcoming clinical trials, and business development and partnering opportunities. The speakers also comment on key corporate development topics around the shareholder support required to authorise new shares for future strategic development and financing.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free